Skip to main content

Zucara Therapeutics Inc.

October 18, 2023
Franciscan B
Metabolic Diseases
Zucara Therapeutics Inc. is developing ZT-01, a first-in-class therapeutic to prevent insulin-induced hypoglycemia (low blood sugar) in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin (SST), a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with Type 1 diabetes and insulin-dependent Type 2 diabetes (T1D). ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life.
Michael Midmer - Zucara Therapeutics Inc.